Background
Introduction
Convergent lines of evidence suggest that immune mechanisms are important for pathogenesis of schizophrenia. There is robust genome-wide association of schizophrenia with single nucleotide variants in the MHC region, in other immune-related genes, and at enhancers expressed in immune cell populations [1, 2] . Imaging and post mortem studies have provided evidence of microglial activation in patients [3] [4] [5] . Animal models of neurodevelopmental aberration and psychotic-like adult behaviours have been generated by maternal infection during pregnancy [6, 7] . Clinical studies of immune biomarker differences between patients with schizophrenia and healthy volunteers have been reported, providing preliminary evidence for diagnostic abnormalities, for example, in cytokines, cell counts, and peripheral gene expression of immune signalling proteins (8) . Transcriptional differences immune genes have mainly reported from microarray analysis of whole blood samples, so that case-control differences in expression cannot be easily disentangled from possible diagnostic differences in the proportions of major immune cell classes (neutrophils, T cells, etc).
It is therefore plausible that evidence of immune-mediated effects on neuronal function, resulting in cognitive impairment or psychotic symptoms, may be found by examining immune cell populations in the peripheral blood. The peripheral immune system and the central nervous system (CNS) functionally communicate with each other by several mechanisms [8, 9] , and may even share some of the same key signalling molecules. For example, classical neurotransmitters such as acetylcholine and dopamine are secreted, and their receptors are expressed, by circulating immune cell populations [10, 11] .
It therefore makes sense to look for immunological biomarkers of schizophrenia using multi-parameter flow cytometry to measure the cellular composition and activation state of immune cell populations in peripheral blood. Flow cytometry studies of schizophrenia to date have been relatively few and limited in scope [12] [13] [14] [15] [16] . There have been several individually robust reports of abnormal immune cell numbers in schizophrenia; but different studies have tended to focus on a limited number of cell types [12] and/or different clinical subgroups, although there is some evidence that first episode and chronic stages of psychotic disorder may be associated with different peripheral immunophenotypes (13) .
Here we report detailed flow cytometry-based immunophenotyping of circulating T-cell, Bcell and myeloid populations from 18 patients with chronic schizophrenia (17 of them currently being treated with clozapine) compared to 20 healthy volunteers. The groups were prospectively matched for some major potential confounders and the patients were clinically characterised in terms of psychotic symptoms, cognitive function and clozapine exposure. We used a panel of markers adapted from that proposed by the Human Immune Phenotyping Consortium [17] to measure 73 immune cell populations. These data were analysed using partial least squares (PLS) regression, a multivariate technique to reduce the dimensionality of the immunological and clinical phenotypes [18] and by so doing mitigate multiple comparisons and allow a few key PLS components, or combinations of immune cell populations, predictive of diagnostic or symptom-related clinical states to be identified. Motivated by the robust prior evidence for CNS dopaminergic signalling as a key mechanism for psychotic symptoms and anti-psychotic drugs [19] , we measured dopamine receptor expression in separated CD4 + Tcells and used PLS to identify the CD4 + T-cell subsets most associated with DRD3 expression.
Material and Methods Design
A cross-sectional case-control design was used to compare a group of patients with chronic schizophrenia and a group of healthy volunteers matched prospectively for mean age, sex, body mass index (BMI) and cigarette smoking; (Table A in S1 File). The study was ethically approved (Health Research Authority NRES Committee East of England-Cambridge South-REC 12/EE/0467). All participants gave informed consent in writing and the consent procedure included a minimum 24 hour period between initial assessment and formal recruitment to allow participants sufficient time to assess the information provided and make a decision. None of the patients were subject to sections of the UK-Mental Health Act.
Sample
We recruited 20 patients aged 18-50 years old with a primary diagnosis of chronic schizophrenia, diagnosed by a consultant psychiatrist (EFE) according to F20.X ICD-10 standards [20] . Patients were recruited principally from a specialist treatment-resistant psychosis service provided by the Cambridgeshire & Peterborough NHS Foundation Trust, UK and satisfied formal criteria for treatment resistant schizophrenia [21] . Most patients in this service are being monitored during clozapine treatment for psychotic symptoms that have not responded to first-line anti-psychotic drugs. 20 healthy volunteers matched by age, gender, smoking status and body mass index were prospectively recruited from the NIHR Cambridge BioResource [22] . Exclusion criteria for both groups included major medical disorders, included allergies and immune illness; current illegal drug use (assessed by the Cannabis Experience Questionnaire [23] ); or current treatment with any immunomodulatory or anti-inflammatory drugs. The study was conducted between April 2013 and May 2014 and cases and controls were recruited in parallel throughout, controlling approximately for seasonal effects on peripheral immune markers.
Clinical and cognitive phenotypes
We collected demographic data, medical and cigarette smoking history by structured interview of all participants. The Brief Assessment of Cognition for Schizophrenia (BACS) [24] was used to summarise overall cognitive performance by a composite Z-score for each subject. Psychotic symptom severity was assessed by an experienced psychiatrist completing the Clinical Global Impression for Schizophrenia (CGI-S) [25] . Types and doses of current psychotropic medication, and the most recent plasma concentrations of clozapine, were ascertained by review of the patients' medical records.
conducted as described in S1 File using the antibody panel described in Table B, Table C and  Table D in S1 File [17] . The gating strategy is outlined in Fig A in 
Statistical analysis of cytometry data
We planned a priori to test two descriptive hypotheses: i) that there are significant case-control differences between patients with schizophrenia and healthy volunteers in the proportions of peripheral immune cells; ii), that there are significant associations between immunological phenotypes and measures of cognitive and clinical symptoms in the patients. We tested both these hypotheses primarily using the multivariate method of partial least squares (PLS). Partial least squares is useful for identifying associations between a set of response variables and a set of predictor variables, especially when the number of predictor variables exceeds the number of observations, and when the predictor variables are highly interdependent or multicollinear [18] . Here, the predictor variables were leukocyte populations expressed in relative terms and measured by flow cytometry. In the first analysis, including schizophrenia cases and healthy volunteers, the response variable was the diagnostic status of each participant (case = 1, control = 0). This yielded a number of PLS components, representing the weighted sums of leukocyte populations most strongly associated with diagnosis. In the second PLS analysis, using data only from the patients, the response variable matrix comprised positive, negative and overall psychotic symptom ratings (CGI-S) and cognitive test scores (BACS), yielding PLS components that could be interpreted as the combination of scaled leukocyte populations most strongly associated with individual differences in cognitive function and psychotic symptoms within the patient group; see S1 File.
To address potentially confounding effects on the case-control comparison, the two groups were prospectively matched for sex, age, BMI, smoking and zero illegal drug use; Table A in S1 File. Prior to the second PLS analysis, the normalised confounding variables above, and clozapine plasma levels (mg/L), were regressed from each response and predictor variable. We used permutation testing to assess the statistical significance of both PLS analyses, and bootstrapping to identify the specific predictor variables (immune cell counts) which made the strongest contributions to explaining the variance in the response variables; see SuppIementary Information.
Dopamine receptor gene expression
The expression levels of all 5 dopamine receptor genes were measured in separated CD4 + Tcells by quantitative polymerase chain reaction (PCR). Only DRD3 and DRD4 expression levels were within the range of the assay; after missing samples were excluded due to low RNA yields there were 16 subjects per group for DRD3 and 15 patients and 16 healthy controls for DRD4.
We tested the case-control difference by a t-test for each gene. We also used PLS to identify which of the CD4 + T-cell subsets were most strongly associated with CD4 + T-cell DRD3 expression.
Results

Sample characteristics
We analysed complete data on 18 patients with treatment resistant schizophrenia (mean duration = 18 years) and 18 healthy volunteers. The two groups were matched in terms of age (mean = 40 years), gender (16/18 male), BMI (mean = 30.5 kg/m 2 ) and smoking habits (1/3 current smokers in each group with mean cigarettes/day = 6); Table A in S1 File. The patients had significant cognitive impairment (BACS Z-score = -1.52 compared with Z~0 in healthy volunteers; P = 4 x 10 −5 ; Table A in S1 File) and residual positive, negative and overall psychotic symptoms, with a mean score of 3/7 on the CGI questionnaire scales; see Table A in S1 File. Most (17/18) patients were receiving clozapine treatment (mean dose = 316 mg/day) and 1 patient was treated with risperidone (6 mg/day).
Immunophenotype of schizophrenia. We first used PLS analysis to identify the immune cell populations most strongly predictive of diagnosis (schizophrenia versus healthy volunteer). The first two PLS components together explained 72% of the variance in the response (diagnosis) and could be used to correctly classify 97% of the subjects in the sample (bootstrap classification accuracy~80%); see The first PLS component (PLS1) accounted for 53% of diagnostic variance and was significantly negatively correlated with BACS scores (Pearson's correlation coefficient, r = -0.46; P = 0.004), i.e., subjects with low BACS scores-indicating cognitive impairment-had positive PLS1 scores. The second PLS component (PLS2) accounted for 19% of diagnostic variance and it was not correlated with BACS scores (r = -0.07, P = 0.7). Scores on both components were not correlated with age, smoking, or BMI over all subjects; nor with clozapine plasma concentration in the schizophrenia group; see Table 1 . Table D in S1 File. Positively weighted populations were relatively increased in patients compared to volunteers; whereas negatively weighted populations were relatively decreased in patients; Fig 1. We explored whether populations weighted significantly on a PLS component were also different in absolute numbers, finding that circulating DCs were also fewer in absolute terms in the schizophrenia group (0.03 ± 0.01 x 10 9 cells/L) compared to healthy volunteers (0.06 ± 0.05 x 10 9 cells/L; t-test, P = 0.008); see Fig 1 and Table G in S1 File. Immunophenotype of cognitive impairment and negative symptoms in schizophrenia. In the second PLS analysis, the response variable was a matrix of 4 clinical and cognitive scores (BACS composite score; overall (O), positive (P) and negative (N) symptom scores on the CGI-S) for each of 18 patients with schizophrenia. The BACS score was negatively correlated with overall symptom severity (measured by CGI-O; r = -0.62) and with negative symptom severity (measured by CGI-N; r = -0.72); i.e., patients with greater cognitive impairment tended to have more severe negative symptoms or a combined cognitive/negative deficit. Psychotic symptom severity and cognitive function were not significantly correlated with age, Table H in S1 File for details.
The first two PLS components explained 63% of the variance in cognitive and symptom severity scores: 47% by PLS1 and 16% by PLS2; the goodness-of-fit was significant by permutation testing (P = 0.03). The first PLS component was negatively correlated with BACS scores (r = -0.52, P = 0.05) and positively correlated with CGI-O (r = 0.68, P = 0.005) and with CGI-N scores (r = 0.70, P = 0.003); Fig 2. The second PLS component was positively, but not significantly, correlated with CGI-P scores (r = 0.48, P = 0.07). In view of the lack of robust association between PLS2 and any clinical variable, we will refrain from interpreting this component as a candidate immunophenotype of psychotic symptoms; see Table I Table E in S1 File for weights on the first two PLS components, for all immune cell classes with Z-normalised absolute weight greater than 1; and Table G in S1 File for absolute cell counts of major leukocyte populations in both groups. (D) Cytometry tree diagram (simplified) showing all cell classes that were strongly positively weighted (4 red boxes), or strongly negatively weighted (8 blue boxes), on either component in people with schizophrenia. Cell classes that were equally strongly negatively weighted on the first component of the second, symptom-related PLS analysis (Fig 2) are highlighted by a black border.
doi:10.1371/journal.pone.0155631.g001 Table 1 . First two PLS component scores for diagnostic and for cognitive and psychotic symptom-related PLS analyses. In both cases, PLS component scores were significantly correlated with cognitive (BACS) or symptom (CGI) scores, but not with confounds (age, smoking, BMI). 
Diagnostic PLS Symptom-Related PLS
Dopamine receptor gene expression
Motivated by the evidence for dopaminergic signalling in the CNS as a key mechanism for pathogenesis and pharmacological treatment of schizophrenia, we tested the mechanistic hypothesis that dopamine receptor expression may also be altered in separated CD4 + T-cells, and that this may be correlated with observed alterations in T-cell subpopulations. Dopamine D3 receptor expression (DRD3) was detected in CD4 + T-cells and was found to be significantly increased in the clozapine-treated schizophrenia group (t = -2.2, df = 30, P = 0.035), but there was no significant difference in DRD4 expression; 
Discussion
Using multivariate analysis of an extensive set of peripheral immune cell populations measured by flow cytometry in this case-control study, we first identified a subset of leukocyte populations that was strongly associated with clozapine-treated schizophrenia. Some of these immune cell populations were proportionally increased in cases, e. 
Case-control and within-group analyses in relation to clozapine treatment
We prospectively matched groups for potentially confounding effects of age, gender, obesity and cigarette smoking. However, clozapine remains an obvious potential confounder: all but one of the patients was medicated with clozapine at the time of blood sampling, whereas none of the controls was medicated. Antipsychotic drugs, including clozapine, are known to have effects on peripheral immune cells [26] [27] [28] [29] . Clozapine in particular is well known to modify the number of circulating myeloid cells in patients; rare but severe episodes of neutropenia are a well-recognised complication of clozapine and the principal reason for regular blood monitoring of clozapine treatment in specialist clinical services. Clozapine is also clinically associated with greater risk of obesity, diabetes mellitus and metabolic syndrome: all of which modify peripheral immune status. Given the almost complete confounding of clozapine treatment and schizophrenia diagnosis in this sample it is not possible to disentangle the extent to which case- + and CD8 + cells, have increased relative counts in more severely symptomatic patients. (C) Using the threshold that bootstrapped Z-normalised absolute weight must be greater than 3, we have highlighted 2 classes that have positive weights, and 6 classes that have negative weights, on the first PLS component. Cell classes that were equally strongly negatively weighted on the first component of the first, diagnostic PLS analysis (Fig 1) are highlighted by a black border. See Table I in S1 File for weights on the first two PLS components, for all immune cell classes with Z-normalised absolute weight greater than 1.
doi:10.1371/journal.pone.0155631.g002
control differences are attributable to the effects of the disorder versus the effects of its treatment. The case-control data are probably therefore best regarded as representative of a subgroup of patients with long-standing (negative and cognitive) psychotic symptoms that have + sub-classes included in the PLS analysis, highlighting the 4 cell classes most strongly related to CD4 + DRD3 expression. Cell classes that were equally strongly negatively weighted in the case-control and withingroup PLS analyses (Figs 1 and 2) are highlighted in bold.
doi:10.1371/journal.pone.0155631.g003 not responded to conventional anti-psychotic drug treatment and have therefore been referred to a specialist NHS treatment service administering and monitoring clozapine for patients with otherwise treatment-resistant schizophrenia.
However, the robustness and specificity of our findings are significantly enhanced by our second analysis, exploring individual differences in cognitive impairment and psychotic symptom severity among the patients with schizophrenia. Since all the participants included in this within-group analysis were exposed to clozapine, the confounding effects of medication should be less severe, and could be statistically mitigated by regression on plasma clozapine levels available for most patients. This analysis identified a number of immune cell populations that were significantly associated with cognitive and psychotic symptom severity within the group of clozapine-treated patients: the strongest positive associations were found for naïve CD4 Some of these findings can be contextualised by previous cytometry studies of schizophrenia [12] and some are unprecedented. Increased NK cell [13, 30] and monocyte [14, 31, 32] counts have been reported in several prior cytometry studies of schizophrenia, are suggestive of innate immune system activation peripherally, and would be consistent with PET imaging and postmortem studies showing increased microglial activation in schizophrenia [3, 4] . To our knowledge, this is the first report of reduced circulating DC numbers in schizophrenia. Similarly, we found reduced proportions of HLADR + Tregs and CD45RA -Tregs: these two markers are overlapping and identify a regulatory T-cell population with a more activated phenotype. These results confirm and extend the one prior study of circulating Tregs in schizophrenia, which found reduced numbers overall [14] in the subgroup with poorer outcome. The prior literature on other T cell subsets in schizophrenia includes repeated observations of an increased proportion of naïve T cells relative to CD45RA -CD4 + T-cells [33, 34] . We extend this observation by showing that the proportion of naive T-cells increased with increasing overall symptom severity, with a concomitant reduction in antigen experienced (CD45RA -) CD4 + T-cells. Thus our results are consistent with prior studies [12] ; but we have measured many immune cell subsets for the first time in relation to psychosis. Indeed some of the populations we have measured, such as CD161 + naïve CD4 + T cells, have not yet been well characterised even in normal populations [35] .
Mechanistic interpretation
It is intriguing to speculate how these findings of abnormal circulating innate and adaptive immune cell populations in clozapine-treated patients could be linked to CNS mechanisms for psychotic symptoms and their drug treatment. It is known that dopaminergic signalling in the CNS is both normally important for cognitive function [36, 37] and abnormally perturbed in schizophrenia [38] ; and that dopamine D2 receptor antagonists are generally effective anti-psychotic drugs [39] . It is increasingly recognised that dopamine signalling also plays a role in the peripheral immune system. Dendritic cells express all five sub-types of dopamine receptors and can synthesise and secrete dopamine [40] . Similarly, T cells have reliably been shown to express dopamine receptors DRD3-5, however the expression of DRD1 and DRD2 remains contentious [41, 42] . Dopaminergic signalling modulates or conditions the outcome of immune synapse formation between antigen presenting cells and naïve T cells [40] . Some early reports have suggested that dopaminergic signalling in the immune system may be abnormal in schizophrenia [41, [43] [44] [45] , in Parkinson's disease [46] (a neurodegenerative disorder of dopaminergic neurons), and following anti-psychotic drug treatment (risperidone) [43] . For example, schizophrenia has been associated with increased numbers of DRD4 cell surfaceexpressing CD4 + and CD8 + T cells [44] ; and increased lymphocyte gene expression of DRD3 [45, 47] (but not DRD4) has been reported in three independent prior studies, including in patients not treated with anti-psychotic drugs [47] . We were therefore motivated to test the mechanistically specific hypotheses that there would be abnormal expression of dopamine receptors by peripheral CD4 + T cells in clozapinetreated patients with schizophrenia; and that immune cell sub-classes in the CD4 + T cell lineage would be associated with individual differences in dopamine receptor expression. Both these predictions were supported. We found significantly higher DRD3 gene expression in CD4 + T cells in schizophrenia; and higher DRD3 expression was associated with proportionally reduced counts of activated and memory Treg cells. One possible explanation for the association between CD4+ DRD3 expression levels and counts of CD4 + sub-classes of cells is that abnormal dopamine receptor expression on naïve T cells could inhibit their differentiation as a result of immune synaptic contact with antigen presenting cells, leading to relatively reduced numbers of committed Treg cells [48, 49] . However, much remains to be discovered about the interactions between peripheral and central dopamine signalling, in health and disease, before we can be confident about the value of immune cell counts or transcripts as biomarkers of psychotic symptom severity, or of anti-psychotic drug treatment or treatment-resistance.
Methodological issues
The strengths of this study include the extensive cytometry measurements, the clinical characterization of the patients, and the novel use of partial least squares to reduce dimensionality and mitigate multiple comparisons. The principal limitations include the simple case-control design and modest sample size. The design is potentially vulnerable to uncontrolled differences between the groups in confounding factors, such as exposure to anti-psychotic drugs [50] . We used regression to control the effects of clozapine exposure (and other potential confounds) on immune and cognitive/behavioural variables; and we showed that clozapine exposure was not significantly associated with any of the key PLS components. However, although clozapine concentrations provide a more precise estimate of peripheral exposure than prescribed dose, they are subject to potentially confounding genetic effects on drug metabolism and pharmacokinetics [51] . The pharmacodynamic effects of clozapine or its metabolites on immune function are currently unclear, which further complicates and could undermine the utility of these statistical procedures to control for the effects of clozapine treatment on the within-group analysis. Clearly, it will be important to replicate these results in larger samples, including studies of treatment-naïve patients. Another limitation of the current study is that we did not directly measure central dopaminergic markers, e.g., using positron emission tomography, and we can therefore only speculate how peripheral immune markers might be related to CNS mechanisms known to be important for pathogenesis and treatment of schizophrenia.
Conclusions
As anticipated by evolving neuroimmunological models of schizophrenia, we conclude that specific combinations of circulating immune cell populations, as measured by flow cytometry, and dopamine receptor expression by these populations, are abnormal in patients with treatmentresistant schizophrenia. Specifically, we highlight the evidence for decreased dendritic cells and committed T or B cells, the evidence for increased NK cells, and the evidence for abnormal dopamine receptor expression on CD4 + cells. Further studies of immune cell counts and transcripts in larger and more diverse clinical samples may lead to the validation of peripherally accessible and mechanistically specific biomarkers of psychosis and/or anti-psychotic drug treatment [52] .
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